Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Teva Pharmaceutical Industries Limited (TEVA) Healthcare & Pipeline Overview

Teva Pharmaceutical Industries Limited stands as a prominent player in the global pharmaceutical sector, delivering a diverse portfolio of generic and specialty medications while focusing on central nervous system, respiratory, and oncology therapies.

What Is the Investment Thesis for TEVA?

The company's market capitalization stands at $42.7B, with a P/E ratio of 57.95, indicating potential undervaluation relative to peers. Teva's ongoing commitment to innovation, particularly in the central nervous system and oncology segments, positions it well for future growth. The company's strong free cash flow of $2.57 billion provides a solid foundation for reinvestment in R&D and expansion initiatives. Furthermore, Teva's strategic collaborations, such as with MedinCell, enhance its product pipeline and market reach. However, potential risks include patent expirations and increasing competition in the generic drug market, which could impact revenue streams. Overall, Teva's established market presence and focus on specialty medications are key value drivers that warrant close attention from investors.

Based on FMP financials and quantitative analysis

TEVA Key Highlights

Market capitalization of $42.7B reflects Teva's significant presence in the pharmaceutical industry.

• P/E ratio of 57.95 indicates potential valuation attractiveness compared to industry averages.
• Profit margin of 9.0% demonstrates operational efficiency in a competitive market.
• Gross margin of 52.0% highlights the company's ability to maintain profitability amid pricing pressures.
• Free cash flow of $2.57 billion supports ongoing investment in research and development.

Who Are TEVA's Competitors?

TEVA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are TEVA's Key Strengths?

Strong market position with a diverse product portfolio.

• Established expertise in generic and specialty pharmaceuticals.
• Robust financial performance with significant free cash flow.
• Global presence enabling access to multiple markets.

What Are TEVA's Weaknesses?

Exposure to patent expiration risks affecting revenue.

• Dependence on a limited number of key products for sales.
• Challenges in maintaining pricing power in a competitive market.
• Potential regulatory hurdles in drug approvals.

What Are the Key Risks for TEVA?

Financial-distress signal — its Altman Z-Score of 0.81 sits in the distress zone (elevated bankruptcy risk).

• Rich valuation — a P/E of 57.95 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
• Insider selling — insiders were net sellers of roughly $23.1M recently.
• Exposure to patent expirations impacting revenue streams.
• Intense competition in the generic drug market affecting pricing.
• Regulatory challenges that may delay product approvals.
• Market volatility that could impact financial performance.

What Are the Growth Opportunities for TEVA?

• Expansion in the Central Nervous System Market: Teva's focus on central nervous system disorders, particularly with products like Copaxone and AUSTEDO, presents a significant growth opportunity. The global CNS market is projected to reach $120 billion by 2027, driven by increasing prevalence of neurological disorders. Teva's established presence and ongoing R&D in this area position it favorably to capture market share.
• With a strong emphasis on innovative therapies and collaborations, Teva can leverage its expertise to enhance treatment options and expand its market footprint.
• Development of Long-Acting Injectable Products: The collaboration with MedinCell to develop long-acting injectable products represents a strategic growth avenue for Teva. The global market for long-acting injectables is anticipated to grow significantly, driven by the demand for improved patient adherence and outcomes. This initiative aligns with Teva's commitment to innovation in treatment delivery.
• Geographic Expansion into Emerging Markets: Teva's international presence allows for potential growth in emerging markets where healthcare access is improving. The pharmaceutical market in regions such as Asia-Pacific is projected to grow at a CAGR of over 8% through 2025, providing Teva with opportunities to expand its reach and product offerings.
• Focus on Biosimilars: As the biosimilars market continues to grow, Teva's investment in this area could yield substantial returns. Teva's expertise in biologics and commitment to developing biosimilars can enhance its competitive positioning.

What Threats Does TEVA Face?

• Intense competition from generic and specialty drug manufacturers.
• Potential for regulatory changes impacting operations.
• Market volatility affecting pricing and profitability.
• Risks associated with product recalls and safety concerns.

What Are TEVA's Competitive Advantages?

• Established brand recognition and trust in the pharmaceutical industry.
• Extensive portfolio of patented and generic products.
• Strong global distribution network enhancing market access.
• Robust R&D capabilities driving innovation in drug development.
• Collaborations with other companies to enhance product offerings.

What Does TEVA Do?

Founded in 1901 and headquartered in Tel Aviv-Yafo, Israel, Teva Pharmaceutical Industries Limited has evolved into one of the world's largest pharmaceutical companies. Initially established as a small wholesale drug business, Teva has grown through strategic acquisitions and a commitment to innovation in drug development. The company specializes in developing, manufacturing, and distributing generic medicines, specialty medicines, and biopharmaceutical products across North America, Europe, and other international markets. Teva's extensive product offerings include sterile products, hormones, high-potency drugs, and cytotoxic substances available in various dosage forms such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. The company has a strong focus on therapeutic areas including the central nervous system, pain management, respiratory health, and oncology. Notable products include Copaxone for multiple sclerosis, AJOVY for migraine prevention, and AUSTEDO for tardive dyskinesia. Teva also offers a range of respiratory products like ProAir and QVAR, as well as oncology drugs such as Bendeka and Treanda. Additionally, Teva collaborates with MedinCell to develop long-acting injectable products for schizophrenia treatment. With approximately 37,000 employees, Teva continues to leverage its global presence and expertise to address healthcare needs worldwide.

What Products and Services Does TEVA Offer?

• Develops and manufactures generic and specialty pharmaceuticals.
• Offers a wide range of dosage forms including tablets, injectables, and creams.
• Focuses on therapeutic areas such as central nervous system, oncology, and respiratory health.
• Collaborates with other companies for innovative drug development.
• Markets and distributes products globally across multiple regions.
• Provides active pharmaceutical ingredients to other manufacturers.

How Does TEVA Make Money?

• Generates revenue through the sale of generic and specialty medicines.
• Engages in partnerships and collaborations for drug development.
• Offers active pharmaceutical ingredients to third-party manufacturers.
• Utilizes a global distribution network to reach diverse markets.
• Invests in research and development to innovate and expand product offerings.

What Industry Does TEVA Operate In?

The pharmaceutical industry, particularly the drug manufacturing sector, is experiencing significant growth driven by increasing global healthcare demands and advancements in medical technology. The market for generic drugs is expected to expand as healthcare providers and patients seek cost-effective treatment options. Teva Pharmaceutical Industries Limited is well-positioned within this landscape, leveraging its extensive product portfolio and global distribution capabilities. The competitive landscape includes key players such as Natera, Inc. (NTRA), Biogen Inc. (BIIB), and DexCom, Inc. (DXCM), each focusing on specialized therapeutic areas. Teva's focus on innovation and specialty medicines differentiates it from competitors primarily focused on generic offerings.

Who Are TEVA's Key Customers?

• Healthcare providers including hospitals and clinics.
• Pharmacies and drugstores distributing medications to patients.
• Government and private health organizations purchasing pharmaceuticals.
• Patients seeking effective and affordable treatment options.
• Other pharmaceutical companies requiring active ingredients.

Over the past six months, Teva Pharmaceutical Industries Limited insiders filed 60 SEC Form 4 transactions — 35 sales and 25 purchases. On net that is roughly 600K shares disposed (about $23.1M), a signal worth weighing alongside the fundamentals.

Teva Pharmaceutical Industries Limited has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 2.2% above estimates on average.

Teva Pharmaceutical Industries Limited's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 0.81 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Teva Pharmaceutical Industries Limited stands at 9.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.8%, showing how much profit it generates from its asset base. TEVA trades at a trailing price-to-earnings ratio of 57.95, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.88 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 1.7%, the inverse of the P/E and a quick read on earnings relative to price.

Teva Pharmaceutical Industries Limited (TEVA) Valuation Context

Valued at $42.7B, TEVA is classified as a large-cap stock. Analyst price targets span from $42.00 to $48.00, with a consensus of $44.75. At the current price of $36.65, that implies approximately 22% upside potential. Relative to its peer group, TEVA's quantitative score of 60/100 is roughly in line with the peer average of 65/100.

TEVA Revenue & Earnings Trend

In Q2 FY2026, TEVA generated $4.14B in top-line revenue, marking a sequential increase of 4.0%. The company recorded a net loss of $576.0M, with diluted EPS of $-0.49. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, TEVA averaged $0.15 in diluted EPS.

Company Profile

Teva Pharmaceutical Industries Limited operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Tel Aviv, IL. The company is led by CEO Richard D. Francis. TEVA has traded publicly since 1982.

TEVA Financials

TEVA Latest News

TEVA Analyst Consensus

TEVA MoonshotScore

Common Questions About TEVA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources